A citation-based method for searching scientific literature

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R Patel, Chao-Hua Chiu, Thomas John, Koichi Goto, Christos S Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu-Chung Li, Young K Chae, Christine H Chung, Gregory A Otterson, Haruyasu Murakami, Chia-Chi Lin, Daniel S W Tan, Hans Prenen, Todd Riehl, Edna Chow-Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R Wilson, Robert C Doebele. Lancet Oncol 2020
Times Cited: 153



Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi, Hyo Sup Shim, Jin-Haeng Chung, Yoon La Choi, Min Jeong Lee, Maria Kim, Joo-Hang Kim, Siraj M Ali, Myung-Ju Ahn, Byoung Chul Cho. J Clin Oncol 2017
Times Cited: 178




List of shared articles



Times cited

Post-chemotherapy and targeted therapy imaging of the chest in lung cancer.
B W Carter, M Altan, G S Shroff, M T Truong, I Vlahos. Clin Radiol 2022
1

Performance of Japanese patients in registrational studies.
Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida,[...]. Jpn J Clin Oncol 2022
0

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Aaron C Tan, Daniel S W Tan. J Clin Oncol 2022
9

A Need for More Molecular Profiling in Brain Metastases.
Erica Shen, Amanda E D Van Swearingen, Meghan J Price, Ketan Bulsara, Roeland G W Verhaak, César Baëta, Brice D Painter, Zachary J Reitman, April K S Salama, Jeffrey M Clarke,[...]. Front Oncol 2022
0

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
0

Novel targeted therapies for advanced non-small lung cancer.
Omar Abughanimeh, Anahat Kaur, Badi El Osta, Apar Kishor Ganti. Semin Oncol 2022
0

Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.
Zachary L Quinn, Julie A Barta, Jennifer M Johnson. Am J Med Sci 2022
0

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
1

Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management.
Fabrizio Tabbò, Marco DE Filippis, Francesca Jacobs, Silvia Novello. Minerva Med 2022
0

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson,[...]. JTO Clin Res Rep 2022
0

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
37

The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non-Small-Cell Lung Cancer.
Daniel Almquist, Vinicius Ernani. JCO Oncol Pract 2021
2

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
4

Breakthrough in targeted therapy for non-small cell lung cancer.
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo. Biomed Pharmacother 2021
19

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
64

Systemic Therapy for Mutation-Driven NSCLC.
Lova Sun, Melina E Marmarelis, Corey J Langer. Semin Radiat Oncol 2021
1

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
18

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021
23

Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy.
Federica Zito Marino, Greta Alì, Francesco Facchinetti, Luisella Righi, Gabriella Fontanini, Giulio Rossi, Renato Franco. Expert Rev Anticancer Ther 2021
3

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
3

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
8

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
Francesco Facchinetti, Antonin Levy, Samy Ammari, Charles Naltet, Pernelle Lavaud, Mihaela Aldea, Damien Vasseur, David Planchard, Benjamin Besse. Cancer Manag Res 2021
2

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
10

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Sergey V Orlov, Aglaya G Iyevleva, Elena A Filippova, Alexandra M Lozhkina, Svetlana V Odintsova, Tatiana N Sokolova, Natalia V Mitiushkina, Vladislav I Tiurin, Elena V Preobrazhenskaya, Alexandr A Romanko,[...]. Transl Oncol 2021
2

Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
1

ROS1 Targeted Therapies: Current Status.
Christine M Azelby, Mandy R Sakamoto, Daniel W Bowles. Curr Oncol Rep 2021
5

Lung Cancer Stem Cells-Origin, Diagnostic Techniques and Perspective for Therapies.
Agata Raniszewska, Iwona Kwiecień, Elżbieta Rutkowska, Piotr Rzepecki, Joanna Domagała-Kulawik. Cancers (Basel) 2021
4

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.
Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier. Int J Mol Sci 2021
7

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.
Xinghao Ai, Qiming Wang, Ying Cheng, Xiaoqing Liu, Lejie Cao, Jianhua Chen, Xiaorong Dong, Jianying Zhou, Yun Fan, Cheng Huang,[...]. J Thorac Oncol 2021
2

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.
Pamela Abdayem, David Planchard. Eur Respir Rev 2021
0

A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Mizuha Haraguchi Hashiguchi, Takashi Sato, Rinako Watanabe, Junko Kagyo, Tomohiko Matsuzaki, Hideharu Domoto, Terufumi Kato, Yoshiro Nakahara, Tomoyuki Yokose, Yukihiko Hiroshima,[...]. Thorac Cancer 2021
1

First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.
Tania Losanno, Cesare Gridelli. Curr Oncol Rep 2021
0

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Barbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, Adrian Sacher, Natasha B Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B Card,[...]. Lung Cancer 2021
12

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
Olga Rodak, Manuel David Peris-Díaz, Mateusz Olbromski, Marzenna Podhorska-Okołów, Piotr Dzięgiel. Cancers (Basel) 2021
10

Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor.
Viola W Zhu, Sai-Hong Ignatius Ou. J Thorac Oncol 2021
0


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy